36.6 F
New York
Wednesday, January 27, 2021

Denbury Resources [NYSE: DNR] Reveals A Prepackaged Chapter 11 Bankruptcy Plan

Must read

JPMorgan [NYSE: JPM] Announced To Initiate A Digital Retail Bank In The United Kingdom

JPMorgan Chase revealed that the company will launch a new digital retail bank in the United Kingdom offering the customer of the region...

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Humanigen Inc revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is...

Synchrony [NYSE: SYF] Announced To Purchase Allegro Credit

Synchrony Financials revealed that the company entered into a definitive contract to Purchase Allegro Credit. Allegro Credit's customer base and merchant network will...

Vericel Corp [NASDAQ: VCEL] Names Joe Mara As The New CFO

Vericel Corporation revealed that the company has named Joe Mara as the CFO of the company. He has over more than 20 years...

Denbury Resources, Inc. [NYSE: DNR] disclosed Wednesday that it has filed for Chapter 11 bankruptcy protection as its performance is dropped because of the reduction in oil and gas prices due to the COVID-19 pandemic. Oil and natural gas company has entered into a Restructuring Support Agreement (RSA) with debtholders.

Denbury has agreed with creditors holding 100% of revolving credit facility loans, approximately 67.2% of second lien notes, and almost 70.8% of convertible notes for a “pre-packaged” plan that will reduce the firm’s $2.1 billion of bond debt.

Shares of Denbury rose 2.78% at $0.25 during the trading of Wednesday. It has a day low range of $0.23 and a day high range of $0.30. Denbury had a trading volume of 6.56 million as compared to the average volume of 30.80 million.

Denbury’s profit margin is 26.10%, and an operating margin is 28.50%. In the past 52-weeks of trading, it has 52-weeks low and high range of $0.16-$1.68, respectively. If we look at its profitability, it has return on assets (ROA) of 6.70%, return on investment (ROI) of 9.80%, and return on equity (ROE) of 23.00%.

During the whole court process, Denbury will continue its daily operations. Its lenders will give a debtor-in-possession (DIP) revolving loan that will “roll” into an exit facility with up to $615 million in availability.

More articles

Latest article

A Paychex [NASDAQ: PAYX] Subsidiary Announces Strategic Collaboration With Zoho Books

SurePayroll, a subsidiary of Paychex company revealed that the company has formed a collaboration with Zoho books. SurePAyroll is a provider of small...

MGP Ingredients [NASDAQ: MGPI] Announced To Acquire Luxco and Its Affiliate Companies

MGP Ingredients  revealed a definitive contract to purchase Luxco, Inc and its affiliated companies. Luxco is an alcohol beverage company with more than 60...

Conformis [NASDAQ: CFMS] Entered A Non-Exclusive agreement with SITES Medical

Conformis Inc revealed that the company inked a development and supply contract with sites medical. Both of the companies will work together to...

Colliers International [NASDAQ: CIGI] Announces Executive Leadership Changes For Australian Business

Colliers International  reported that the company has named Malcom Tyson as the new Chief Executive Officer. He is appointed as the CEO so...

Korn Ferry [NYSE: KFY] Announces Expansion Of Its Footprint In Russian Market

Korn Fery revealed that the company is expanding its footprint in Russia. Moreover, it is adding a high expertise team of executive search...

Haemonetics [NYSE: HAE] To Purchase Cardiva For An Upfront Payment Of $475M

Haemonetics Corporation revealed that the company has inked a definitive contract to purchase Cardiva Medical Inc. Under the contract, Haemontics will pay an...

Philips [NYSE: PHG] To Purchase Capsule Technologies For Cash Consideration Of USD 635M

Koninklijke Philip revealed that the company has inked a contract to purchase Capsule technologies. The company will pay a cash price of $636...

Thermo Fisher Scientific [NYSE: TMO] To Purchase Mesa Biotech For Approx. $450M In Cash

Thermo fisher scientific inc revealed that the company has signed a definitive contract to purchase Mesa Biotech. Thermo will pay a value price...